scholarly journals Diffuse Liver Metastasis of Small-Cell Lung Cancer Presenting as Acute Liver Failure and Diagnosed by Transjugular Liver Biopsy: A Rare Case in Whom Nodular Lesions Were Detected by Enhanced CT Examination

2015 ◽  
Vol 9 (1) ◽  
pp. 81-87 ◽  
Author(s):  
S. Mishima ◽  
Y. Nozaki ◽  
S. Mikami ◽  
E. Kihira ◽  
M. Iikura ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Liver Metastasis ◽  
Liver Biopsy ◽  
Liver Failure ◽  
Acute Liver Failure ◽  
Liver Metastases ◽  
Small Cell ◽  
Small Cell Lung ◽  
Enhanced Ct ◽  
Nodular Lesions

Small-cell lung cancer (SCLC) is a subgroup of lung cancer with a high frequency of liver metastasis, which is a predictor of poor prognosis. Diffuse liver metastases of SCLC with no visible nodular lesions in the liver when examined using computed tomography (CT) are relatively rare; however, a few cases with rapid progression to acute liver failure that were diagnosed after death have been reported. In this paper, we report a 63-year-old man with diffuse liver metastases of SCLC that were histologically diagnosed using a transjugular liver biopsy while the patient was alive, even though no lesions were visible during a contrast-enhanced CT examination.

Detection of liver metastases in small-cell lung cancer: a comparison of peritoneoscopy with liver biopsy and ultrasonography with fine-needle aspiration.

1987 ◽  
Vol 5 (2) ◽  
pp. 255-259 ◽  
Author(s):  
S W Hansen ◽  
F Jensen ◽  
N T Pedersen ◽  
A G Pedersen ◽  
H H Hansen
Keyword(s):  
Lung Cancer ◽  
Liver Biopsy ◽  
Liver Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Fine Needle Aspiration ◽  
Needle Aspiration ◽  
Small Cell ◽  
Small Cell Lung ◽  
Fine Needle

Liver evaluation of 131 patients with small-cell lung cancer (SCLC) was performed both by peritoneoscopy (PS) with liver biopsy and by ultrasonography (US) with fine-needle aspiration. A total of 33 patients (25%) had liver involvement, 82% detected by US and 76% detected by PS. The difference was due to 27 incomplete investigations by PS and two incomplete investigations by US. In 104 patients in whom both investigations were "successful," PS confirmed 86% and US confirmed 79% of the patients with liver metastases. In each of the investigations, 7% (PS) and 14% (US) of patients had false-negative conclusions as compared with histologic evidence obtained by the other method. US found six patients with extrahepatic intraabdominal disease, while PS found none. S-lactic dehydrogenase (s-LDH), SGOT, and s-alkaline phosphatase were found to be too unspecific to indicate liver metastases unless all three tests were normal or abnormal. It is recommended that US should be used as the initial procedure when staging patients with SCLC, and that PS can be considered complementary in patients with negative US.

scholarly journals Fatty liver is a risk factor for liver metastasis in Chinese patients with non-small cell lung cancer

PeerJ ◽  
2019 ◽  
Vol 7 ◽  
pp. e6612 ◽  
Author(s):  
Wenyu Wu ◽  
Haiyan Liao ◽  
Weilin Ye ◽  
Xi Li ◽  
Jian Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Risk Factor ◽  
Liver Metastasis ◽  
Liver Metastases ◽  
Small Cell Lung Cancer ◽  
Hepatic Steatosis ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
The Impact

Background The hepatic microenvironment, which may include chronic inflammation and fibrosis, is considered to contribute to the development of liver metastases. Hepatic steatosis (HS) might cause liver inflammation and fibrosis. However, to date, no studies have investigated the impact of HS on liver metastasis in patients with non-small cell lung cancer (NSCLC). Methods A retrospective cohort study was performed on patients who received NSCLC treatment at two hospitals affiliated with the Southern Medical University from January 2005 to December 2015. The patients were grouped according to the presence of HS. The clinicopathological features of patients between the two groups were compared. The effect of HS on liver metastasis and overall metastasis was evaluated, adjusting for other confounders using Cox regression analyses. Results In total, 1,873 patients with NSCLC with no distant metastases were included in this study, and 408 (21.8%) patients were diagnosed with HS (at the time of diagnosis or before diagnosis). Liver metastases occurred in 166 (8.9%) patients. Liver metastasis-free survival was significantly worse in the study (HS) group (hazard ratio (HR) 1.42; (95% CI [1.03–1.96]); P = 0.031). Multivariate regression analysis demonstrated that HS was an independent risk factor for liver metastasis (HR 1.43; 95% CI [1.02–2.01]; P = 0.039). However, HS was not associated with overall metastasis of NSCLC (HR 0.99; 95% CI [0.84–1.17]; P = 0.895). Conclusion Hepatic steatosis was an independent predictor of liver metastasis from in patients with NSCLC.

Phenotype of acute liver failure in inapparent small cell lung cancer

2020 ◽  
Vol 74 (5) ◽  
pp. 404-409
Author(s):  
Xénia Faktorová ◽  
Terézia Staškovanová ◽  
Katarína Bilíková ◽  
Richard Hokša ◽  
Tomáš Tvrdík ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Liver Failure ◽  
Acute Liver Failure ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Primary Tumour ◽  
Small Cell ◽  
Rapid Progression ◽  
Small Cell Lung ◽  
Elevated Liver Enzymes

Acute liver failure is defined by the manifestation of liver failure from 7th to 21st day in a previously healthy liver. The most frequent causes are viral hepatitis B, A, E, drug or toxin-induced hepatotoxicity (Amanita phalloides), rarely Wilson’s disease, autoimmune hepatitis, HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome, or vascular causes (Budd-Chiari syndrome, hypoxic hepatitis). We present a 71-year- -old female patient with metabolic syndrome admitted to hospital with cholestasis, progression of weakness, abdominal pain, and breathlessness. Because of suspected pleuropneumonia, the treatment with ceftriaxone/metronidazole was initiated. Due to cholestasis progression and suspicion of drug-induced liver toxicity, the treatment was stopped on 5th day. Imaging methods (ultrasonography, CT, magnetic resonance imaging) found multiple small liver lesions, suspected metastatic involvement, which was not confirmed by positron emission tomography – computed tomography. Due to the rapid progression of the patient’s condition with the onset of icterus, ascites, encephalopathy, a liver bio­psy was not done. The patient died on the 17th day of hospitalization. The primary tumour was not detected during her life, and not by pathological section. The diffuse metastasis of small cell lung cancer (SCLC) in the liver was found by histological post mortem examination. The case report suggests high invasiveness of SCLC with a possibility of unusual manifestation in a form of acute hepatic failure.

scholarly journals Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT

2017 ◽  
Vol 56 (11) ◽  
pp. 1591-1596 ◽  
Author(s):  
Aniek J. G. Even ◽  
Bart Reymen ◽  
Matthew D. La Fontaine ◽  
Marco Das ◽  
Arthur Jochems ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Fdg Pet ◽  
Tumor Hypoxia ◽  
Small Cell ◽  
Small Cell Lung ◽  
Dynamic Contrast Enhanced ◽  
Contrast Enhanced Ct ◽  
Contrast Enhanced ◽  
Enhanced Ct ◽  
Dynamic Contrast Enhanced Ct
Sign in / Sign up

Export Citation Format

Share Document